Trials / Active Not Recruiting
Active Not RecruitingNCT07232719
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
A Phase 3b Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 250 (estimated)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of retatrutide compared with placebo for body weight reduction. Participation in the study will last about 65 weeks and may include about 18 visits.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Retatrutide | Administered SC |
| DRUG | Placebo | Administered SC |
Timeline
- Start date
- 2025-11-17
- Primary completion
- 2027-07-01
- Completion
- 2027-07-01
- First posted
- 2025-11-18
- Last updated
- 2026-04-17
Locations
31 sites across 2 countries: United States, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07232719. Inclusion in this directory is not an endorsement.